NCT03754309 is a Phase 2 clinical trial of KY1005 in Dermatitis, Atopic, sponsored by Kymab Limited.

Who is sponsoring NCT03754309?

NCT03754309 is sponsored by Kymab Limited.

What drugs are being tested in NCT03754309?

Interventions in NCT03754309: KY1005, Placebo.

What condition does NCT03754309 study?

NCT03754309 studies Dermatitis, Atopic.

Is NCT03754309 still recruiting?

NCT03754309 is currently completed. Last updated 27 January 2023.

Last reviewed 2023-01-27 · How we verify

NCT03754309

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

Completed Phase 2 Last updated 27 January 2023

What this trial tests

Phase 2 trial testing KY1005 in Dermatitis, Atopic in 89 participants. Completed in 8 October 2020.

Timeline

13 December 2018

Primary endpoint
12 May 2020

8 October 2020

Quick facts

Lead sponsor	Kymab Limited
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	89
Start date	13 December 2018
Primary completion	12 May 2020
Estimated completion	8 October 2020
Sites	19 locations across Spain, United Kingdom, Germany, Poland

Drugs / interventions tested

KY1005 — full drug profile →
Placebo

Conditions studied

Dermatitis, Atopic — all drugs for Dermatitis, Atopic →

Sponsor

Kymab Limited — full company profile →

Who can join

Adults 18 to 75, any sex, with Dermatitis, Atopic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to investigate if KY1005 results in improvement of eczema when given to participants with moderate to severe disease. Side effects of KY1005 will also be explored.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.
Bieber T. · · 2022 · cited 421× · PMID 34417579 · DOI 10.1038/s41573-021-00266-6
The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.
Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. · · 2023 · cited 150× · PMID 36928371 · DOI 10.1038/s41423-023-00992-4
T cell pathology in skin inflammation.
Sabat R, Wolk K, Loyal L, Döcke WD, et al · · 2019 · cited 134× · PMID 31028434 · DOI 10.1007/s00281-019-00742-7
Cytokines and costimulation in acute graft-versus-host disease.
Hill GR, Koyama M. · · 2020 · cited 100× · PMID 32526028 · DOI 10.1182/blood.2019000952
OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab.
Lé AM, Torres T. · · 2022 · cited 60× · PMID 36559247 · DOI 10.3390/pharmaceutics14122753
TNF superfamily control of tissue remodeling and fibrosis.
Steele H, Cheng J, Willicut A, Dell G, et al · · 2023 · cited 50× · PMID 37465675 · DOI 10.3389/fimmu.2023.1219907
Systemic treatments for eczema: a network meta-analysis.
Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, et al · · 2020 · cited 30× · PMID 32927498 · DOI 10.1002/14651858.cd013206.pub2
Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives.
Pareek A, Kumari L, Pareek A, Chaudhary S, et al · · 2024 · cited 27× · PMID 38474389 · DOI 10.3390/cells13050425

Verify or expand the search:

Other trials of KY1005

Trials testing the same drug.

NCT04449939 — A Study of Subcutaneous KY1005 in Healthy Volunteers · Phase 1 · completed
NCT03161288 — A Study of KY1005 in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Dermatitis, Atopic

Currently open trials in the same condition.

NCT07230860 — A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
NCT06899204 — Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate · recruiting
NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
NCT06881251 — A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) · Phase 2 · active not recruiting
NCT06554847 — Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis · Phase 3 · active not recruiting

Other Kymab Limited trials

Trials by the same sponsor.

NCT05131477 — Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study · Phase 2 · completed
NCT04449939 — A Study of Subcutaneous KY1005 in Healthy Volunteers · Phase 1 · completed
NCT03829501 — A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Co · Phase 1, PHASE2 · terminated
NCT03161288 — A Study of KY1005 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03754309 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kymab Limited
Last refreshed: 27 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03754309.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing